Author:
Tran D.,Cren P.,Capdeville A.
Reference10 articles.
1. European Medicines Agency (2017) PRAC concludes assessment of gadolinium agents used in body scans and recommends regulatory actions, including suspension for some marketing authorizations. http://www.ema.europa.eu/docs/en_GB/document_library/ Press_release/2017/03/WC500223209.pdf (Dernier accès 4 septembre 2017)
2. Ishiguchi T, Takahashi S (2010) Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan. Drugs R D 10:133–45
3. Herborn CU, Honold E, Wolf M, et al (2007) Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol 42:58–62
4. Demirhan A, Yasar Tekelioglu U, Akkaya A, et al (2012) Magnetic resonance imaging contrast agent related pulmonary edema: a case report. Eur Rev Med Pharmacol Sci 16(Suppl 4):110–2
5. Gupta N, Davidson J, Li A (2013) Acute respiratory distress syndrome due to gadolinium administration. J Intensive Care Soc 14:159–62